Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Biomarkers in Pulmonary Hypertension Associated to Interstitial Lung Disease

This study has been completed.
Information provided by (Responsible Party):
Charlotte Andersen, University of Aarhus Identifier:
First received: January 9, 2009
Last updated: September 17, 2012
Last verified: September 2012

The presence of an abnormally increased pulmonary blood pressure worsens the prognosis of patients with interstitial pulmonary disease.

The aim of this study is to estimate the frequency of an increased blood pressure in the lungs among patient with interstitial pulmonary disease, and to evaluate the use of different biomarkers in diagnosis of the condition.

Interstitial Lung Disease
Pulmonary Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Prevalence of Pulmonary Hypertension and the Significance of Different Biomarkers in Chronic Interstitial Lung Disease

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Biospecimen Retention:   Samples With DNA
blood samples

Enrollment: 212
Study Start Date: March 2009
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Patients with interstitial pulmonary disease

Detailed Description:

The presence of increased pulmonary blood pressure is established by echocardiography and confirmed by right heart catheterization.

The ability of NT-proBNP, vWf, troponin-t, D-dimer and exhaled NO to predict the presence of increased pressure in the pulmonary circulation is evaluated.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Out-patients with interstitial pulmonary disease.

Inclusion Criteria:

  • Interstitial pulmonary disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00820729

Department of Cardiology, Skejby sygehus
Århus N, Denmark, DK-8200
Department of Pulmonary Diseases, Århus Sygehus
Århus, Denmark, Dk-8000
Sponsors and Collaborators
University of Aarhus
  More Information

Responsible Party: Charlotte Andersen, MD, University of Aarhus Identifier: NCT00820729     History of Changes
Other Study ID Numbers: Fibrosis-ECHO 2009 
Study First Received: January 9, 2009
Last Updated: September 17, 2012
Health Authority: Denmark: Ethics Committee

Keywords provided by University of Aarhus:
interstitial lung disease
pulmonary hypertension
von Willebrand factor
Exhaled NO

Additional relevant MeSH terms:
Lung Diseases
Hypertension, Pulmonary
Lung Diseases, Interstitial
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases processed this record on October 27, 2016